Exclusive Summary

• Holds dual US-FDA and UK-MHRA GMP certifications and US registration, enabling prospective distributors to accelerate market entry in emerging markets (SEA, MENA, LATAM) via US CPP reliance pathways.
• Features a comprehensive dosage range (50/100/200/400mg) that covers all indications from pediatric dose-titration to acute severe pain, providing a much stronger portfolio barrier than standard generic competitors.
• Represents the standard-of-care COX-2 inhibitor with superior GI safety, anchoring a massive and highly recurring prescription baseline driven by over 500 million arthritis patients globally.
• Leverages China's advanced manufacturing supply chain to offer top-tier Western quality at highly competitive B2B supply margins, ensuring lucrative profitability for global distribution networks.